

## Syntara appoints new CFO

Clinical stage drug development company Syntara Limited (ASX: SNT) is pleased to announce the appointment of Tim Luscombe as Chief Financial Officer (CFO) for Syntara, effective 31 August 2024.

Tim replaces Mr David McGarvey, who is retiring after more than 20 years as the CFO of Syntara, and before that Pharmaxis. David will continue in his role as Company Secretary to the Board.

Tim is a Director at Bio101 Financial Advisory (Bio101), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. Tim has more than 10 years of finance and commercial experience working with public and private companies in Australia and abroad. He currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies. Tim holds a Bachelor of Commerce from the University of Melbourne, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.

Syntara CEO Gary Phillips, said: "As well as welcoming Tim to the Syntara leadership team I'd like to thank David for his steadfast commitment, sound advice and support to the management and Board of Syntara over many years. We are delighted that David has agreed to continue his engagement with the Board as Company Secretary, where his in-depth knowledge of our business will prove invaluable as we finalise the restructuring of our business following the sale of the mannitol business unit last year."

In addition to his role as Company Secretary Mr McGarvey will give special attention to concluding financial and legal arrangements associated with the sale of the mannitol business unit.

#ENDS#

**SOURCE:**

Syntara Limited (ASX: SNT),  
Sydney, Australia  
(ABN: 75 082 811 630)

**AUTHORISED FOR RELEASE TO ASX BY:**

Syntara Limited Disclosure Committee.  
Contact: David McGarvey, Chief Financial  
Officer, and Company Secretary:

+61 2 8760 1480  
[david.mcgarvey@syntaraTX.com.au](mailto:david.mcgarvey@syntaraTX.com.au)

**CONTACT:****Syntara investor / media relations:**

Matthew Wright  
NWR Communications  
+61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**[JOIN THE SYNTARA MAILING LIST HERE](#)**





## About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Syntara is managing three phase 2 clinical studies in diseases of high unmet need with a further two potential phase 1c/2 studies being evaluated for 2024. Lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. After encouraging phase 2a trial results when used as a monotherapy in myelofibrosis, SNT-5505 is now being studied with a JAK inhibitor in a further phase 2 myelofibrosis study with interim data by Q4 2024. Protocols for another two phase 1c/2 studies with SNT-5505 in patients with a blood cancer called myelodysplastic syndrome are in development and expected to commence recruitment by Q1 2025.

Syntara is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs as part of an ongoing collaboration with Professor Fiona Wood and the University of Western Australia. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. [www.syntaraTX.com.au](http://www.syntaraTX.com.au).

## Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.